Neurolixis Appoints Steven A. Johnson, Ph.D. to Management Team

Dana Point, 16 November, 2015 – Neurolixis Inc., a privately held biotechnology company developing therapies for disorders of the central nervous system (CNS), today announced that it had appointed Steven A. Johnson, Ph.D., to its executive management team as Vice President for Drug Development.

Dr. Johnson has extensive experience in the pharmaceutical industry, where he has led clinical development teams developing therapeutics targeting neurologic and psychiatric diseases such as Alzheimer's disease, Parkinson's disease, schizophrenia, depression and ADHD. Dr. Johnson also has wide-ranging expertise in the preclinical development of pharmacological agents and preparation and submission of regulatory documents.

"It is a pleasure to welcome Steve to Neurolixis as VP for Clinical Development," commented Mark Varney, Ph.D., CEO, "his thoughtful approach to CNS drug development will facilitate the progress of the Neurolixis clinical candidates."

Dr. Johnson previously held a series of management positions at Cortex Pharmaceuticals (Irvine, CA), including Vice-President for Development and Executive Officer. Prior to Cortex, he was Assistant Professor of Gerontology at University of Southern California (USC). Dr. Johnson gained his Ph.D. at Purdue University (Indiana) and carried out post-doctoral research at the California Institute of Technology (CalTech; Pasadena) and at USC.

About Neurolixis, Inc.

Neurolixis, located in Dana Point, California, is a privately held biotechnology company developing small molecule drugs for the treatment of neurological disorders such as Parkinson's disease and Rett syndrome and of psychiatric disorders such as depression and schizophrenia. Additional information is available at http://www.neurolixis.com.

Forward Looking Statement

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Neurolixis disclaims any intent or obligation to update these forward-looking statements.

PRESS CONTACTS

Dr Mark Varney, CEO Neurolixis,
contact@neurolixis.com